NEW YORK (GenomeWeb) — Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week. Wilmington, Massachusetts-based Kapa develops genomics tools. Its acquisition will add to Roche's NGS portfolio by building on its existing NGS target enrichment products, Roche said. Terms of the deal were undisclosed.
Danaher announced this week that its board of directors has approved a quarterly share dividend of $.135 per share, which will be paid on Jan. 29, 2016 to holders of record on Dec. 21, 2015.